Nonmyeloablative conditioning for stem cell allografts with low-dose tbi

BM Sandmaier(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Dietger Niederwieser(Leipzig University of Applied Sciences), Jerald P. Radich(University of Washington), A Molina(University of Washington), Peter A. McSweeney(Mesoblast (United States)), Karl G. Blume(City Of Hope National Medical Center), T Chauncey, Judith A. Shizuru(Stanford University), DG Maloney, Ted Gooley(Fred Hutch Cancer Center)
Experimental Hematology
July 1, 2000
10.1016/s0301-472x(00)00276-9
Cited by 2

Related Papers

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k